We are excited to have this trial open for patients with #metastatic #breastcancer treated an NCI community oncology practices #NCORP ECOG-ACRIN Cancer Research Group Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) Ruth Carlos @ilana_graetz Lynne I Wagner PhD

What a trio of ACRA Award recipients, including Johns Hopkins Kimmel Cancer Center JHBreastGynResearch Cesar Santa-Maria, MD! Congratulations to all in the Class of #ASCO24 Conquer Cancer, the ASCO Foundation awardees and their mentors! ASCO

Training & Promoting the next generation of breast cancer leaders, and of course designing the next generation of trials to improve patient outcomes.

This is what qualifies for an oncologist to be in the presence of a rock star ⁦⁦@NIHDirector⁩ ! #asco24 ⁦Judy Gichoya⁩ ⁦Suresh S. Ramalingam, MD, FASCO⁩

TBCRC058 aims to evaluate treatment in metastatic ER-negative / ER-low AR+ breast cancer. Learn more about the study at #ASCO24 Translational Breast Cancer Research Consortium

ETHAN - groundbreaking new Translational Breast Cancer Research Consortium trial for male breast cancer led by PI Dr. Pablo Leone. #ASCO24 Learn more at classic.clinicaltrials.gov/ct2/show/NCT05…

In case you missed Guilherme Nader Marta Erica Mayer poster on TBCRC030! #ASCO24

PI Dr. Tiffany Traina presenting the actively enrolling TBCRC058 trial #ASCO24 Rita Nanda Find more info at: classic.clinicaltrials.gov/ct2/show/NCT06…

Tomorrow #ASCO24 check out Nadine Tung MD present #TBCRC048 olaparib expanded cohorts of gPALB2 and sBRCA MBC, one of the most rewarding studies I’ve managed in the last decade and a testament to the power of investigator-initiated research BIDMC Dana-Farber’s Breast Oncology Center Translational Breast Cancer Research Consortium

TBCRC048 is a collaborative IST led by #DFHCC and was open at 11 academic centers across the US via Translational Breast Cancer Research Consortium - thank you to the incredibly dedicated study teams at each of the sites and, most importantly, the 114 participants, many of whom traveled great distances for the study

#ASCO24 Translational Breast Cancer Research Consortium

As seen today at #ASCO24 - TBCRC026, HER2-E and tumors with increased immune signaling more likely to respond to HER2-directed therapy in ER-/HER2+ breast cancer treated with neoadjuvant HP without chemo. Translational Breast Cancer Research Consortium Maeve Hennessy

#TrialsThatImpactPatientCare Congratulations to the ECOG-ACRIN Cancer Research Group EAZ171 Team! #ASCO24 See full press release ecog-acrin.org/press-release-… and simultaneous JCO paper ascopubs.org/doi/10.1200/JC…

RxPONDER: AMH (low levels associated w/ diminished ovarian reserve) in women classified as premenopausal If low AMH --> no benefit from adj chemo If med/high AMH--> ⬆️4.4% in 5 yr DRFS w/ chemo Suggests:chemo impact may be due to impact on ovarian fxn OncoAlert #ASCO24

Dr. Nadine Tung discusses TBCRC048 at #ASCO24 - olaparib is effective in patients with MBC with inherited PALB2 mutation or tumor acquired BRCA1 or BRCA2 mutation. Benefit in initial trial confirmed in a larger group of patients Translational Breast Cancer Research Consortium OncoAlert

So grateful, Tarah Ballinger, MD. We are privileged that you chose to bring your brilliance to ECOG-ACRIN Cancer Research Group and brighten the work we do to improve care for our patients. NCI Cancer Control #ASCO24

It was a treat to do the Highlights of the Day I - Breast Ca Metastatic, and contextualize the great work of presenters and discussants. Thou shalt not forget to watch the fantastic talk by discussant Mayo Clinic Dr. Ciara O'Sullivan.

We are grateful for the support of The Breast Cancer Research Foundation & Susan G. Komen. See you soon at #SABCS24!

#SABCS24 Dr. Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy): Must study impact of new #cancer drugs on reproductive health. ⌛️ He believes we are under-utilizing ovarian suppression & over-utilizing chemo in premenopausal w/ #breastcancer, & window to answer this Q definitively in #bcsm #clinicaltrials is closing.

Don’t miss Dr. Erica Mayer (Erica Mayer) presenting results from a Phase II study on neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated #BreastCancer, focusing on the ER+/HER2- cohort, at the #SABCS24 Rapid Fire 3 session. Translational Breast Cancer Research Consortium 🗓️ Friday,